AstraZeneca’s CHRONICLES COPD Study: A New Horizon in COPD Treatment

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

Study Overview: AstraZeneca is conducting a study titled Chronicling the COPD Patient Journey and Change in Impact of a Single Inhaler Combination Therapy on COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF] (CHRONICLES COPD). The study aims to evaluate changes in clinical and patient-reported outcomes over six months following the initiation of BGF treatment in COPD patients, highlighting its significance in improving patient quality of life.

Intervention/Treatment: The intervention being tested is a drug combination of Budenoside, Glycopyrronium, and Formoterol (BGF). This single inhaler therapy is intended to manage COPD symptoms, improve quality of life, and reduce exacerbations.

Study Design: This is an observational, prospective cohort study conducted in a real-world clinical setting in Ontario, Canada. The study does not involve random allocation or masking, focusing instead on observing the outcomes of patients who begin BGF treatment as part of their routine care.

Study Timeline: The study began on September 17, 2024, with primary completion expected six months post-treatment initiation. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and study progress.

Market Implications: This study update could positively influence AstraZeneca’s stock performance by demonstrating the effectiveness of BGF in managing COPD, potentially boosting investor confidence. As the COPD treatment market is competitive, successful outcomes could strengthen AstraZeneca’s position against competitors.

The study is ongoing, with further details available on the ClinicalTrials portal.